

Anifrolumab Malignancy and Serious Infections Study

NCT07000110

Status RECRUITING
Sponsor AstraZeneca
Enrollment 3,195 participants

Key Eligibility Criteria

Inclusion (5)

- First prescription of anifrolumab in the study period (no anifrolumab prescription prior to index date): date of first anifrolumab prescription will be the index date
- A minimum data availability of 12 months prior to index date
- Age ≥18 years at index date
- SLE severity: patients with moderate to severe SLE at index date
- SLE activity: patients with at least a flare (uncontrolled SLE) in the 6 months prior to index date

Exclusion (4)

- A diagnosis of any malignancy prior to index date
- A diagnosis of HIV/AIDS or congenital immunodeficiency prior to index date
- Organ or bone marrow transplant procedure prior to index date
- A diagnosis of serious infection in the previous 6 months

Locations (4 total)

Research Site, Copenhagen, Denmark
Research Site, Charenton-le-Pont, France
Research Site, Essen, Germany
... and 1 more locations